HLA-E: Presentation of a Broader Peptide Repertoire Impacts the Cellular Immune Response-Implications on HSCT Outcome

Overview

Journal Stem Cells Int

Publisher Wiley

Specialty Cell Biology

Date 2015 Sep 15

PMID 26366178

Citations 40

Authors

Thomas Kraemer

Alexander A Celik

Trevor Huyton

Heike Kunze-Schumacher

Rainer Blasczyk

Christina Bade-Doding

Affiliations

Soon will be listed here.

Abstract

The HLA-E locus encodes a nonclassical class Ib molecule that serves many immune functions from inhibiting NK cells to activating CTLs. Structural analysis of HLA-E/NKG2A complexes visualized fine-tuning of protective immune responses through AA interactions between HLA-E, the bound peptide, and NKG2A/CD94. A loss of cellular protection through abrogation of the HLA-E/NKG2A engagement is dependent on the HLA-E bound peptide. The role of HLA-E in posttransplant outcomes is not well understood but might be attributed to its peptide repertoire. To investigate the self-peptide repertoire of HLA-E (∗) 01:01 in the absence of protective HLA class I signal peptides, we utilized soluble HLA technology in class I negative LCL cells in order to characterize HLA-E (∗) 01:01-bound ligands by mass-spectrometry. To understand the immunological impact of these analyzed ligands on NK cell reactivity, we performed cellular assays. Synthesized peptides were loaded onto recombinant T2 cells expressing HLA-E (∗) 01:01 molecules and applied in cytotoxicity assays using the leukemia derived NK cell line (NKL) as effector. HLA-E in complex with the self-peptides demonstrated a shift towards cytotoxicity and a loss of cell protection. Our data highlights the fact that the HLA-E-peptidome is not as restricted as previously thought and support the suggestion of a posttransplant role for HLA-E.

Citing Articles

Deciphering the HLA-E immunopeptidome with mass spectrometry: an opportunity for universal mRNA vaccines and T-cell-directed immunotherapies.

Weitzen M, Shahbazy M, Kapoor S, Caron E Front Immunol. 2024; 15:1442783.

PMID: 39301027 PMC: 11410602. DOI: 10.3389/fimmu.2024.1442783.

A monoclonal antibody that recognizes a unique 13-residue epitope in the cytoplasmic tail of HLA-E.

Verhaar E, Gan J, Buhl S, Li Z, Horowitz A, Ploegh H Mol Immunol. 2024; 172:56-67.

PMID: 38901180 PMC: 11257791. DOI: 10.1016/j.molimm.2024.06.004.

CRISPR-Cas9 immune-evasive hESCs are rejected following transplantation into immunocompetent mice.

Frederiksen H, Glantz A, Vols K, Skov S, Tveden-Nyborg P, Freude K Front Genome Ed. 2024; 6:1403395.

PMID: 38863835 PMC: 11165197. DOI: 10.3389/fgeed.2024.1403395.

SARS-CoV-2 infection induces adaptive NK cell responses by spike protein-mediated induction of HLA-E expression.

Hasan M, Claus M, Kruger N, Reusing S, Gall E, Bade-Doding C Emerg Microbes Infect. 2024; 13(1):2361019.

PMID: 38804979 PMC: 11212573. DOI: 10.1080/22221751.2024.2361019.

SARS-CoV-2 viral persistence in lung alveolar macrophages is controlled by IFN-γ and NK cells.

Huot N, Planchais C, Rosenbaum P, Contreras V, Jacquelin B, Petitdemange C Nat Immunol. 2023; 24(12):2068-2079.

PMID: 37919524 PMC: 10681903. DOI: 10.1038/s41590-023-01661-4.

References

Allard M, Tonnerre P, Nedellec S, Oger R, Morice A, Guilloux Y . HLA-E-restricted cross-recognition of allogeneic endothelial cells by CMV-associated CD8 T cells: a potential risk factor following transplantation. PLoS One. 2012; 7(11):e50951. PMC: 3511380. DOI: 10.1371/journal.pone.0050951. View

Petersdorf E . Risk assessment in haematopoietic stem cell transplantation: histocompatibility. Best Pract Res Clin Haematol. 2007; 20(2):155-70. PMC: 3680359. DOI: 10.1016/j.beha.2006.09.001. View

Andre P, Castriconi R, Espeli M, Anfossi N, Juarez T, Hue S . Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors. Eur J Immunol. 2004; 34(4):961-71. DOI: 10.1002/eji.200324705. View

Rolle A, Pollmann J, Ewen E, Le V, Halenius A, Hengel H . IL-12-producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell expansion. J Clin Invest. 2014; 124(12):5305-16. PMC: 4348979. DOI: 10.1172/JCI77440. View

Robertson M, Cochran K, Cameron C, Le J, Tantravahi R, Ritz J . Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol. 1996; 24(3):406-15. View

Borrego F, ULBRECHT M, Weiss E, Coligan J, Brooks A . Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med. 1998; 187(5):813-8. PMC: 2212178. DOI: 10.1084/jem.187.5.813. View

Braud V, Jones E, McMichael A . The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur J Immunol. 1997; 27(5):1164-9. DOI: 10.1002/eji.1830270517. View

Emsley P, Lohkamp B, Scott W, Cowtan K . Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010; 66(Pt 4):486-501. PMC: 2852313. DOI: 10.1107/S0907444910007493. View

Heatley S, Pietra G, Lin J, Widjaja J, Harpur C, Lester S . Polymorphism in human cytomegalovirus UL40 impacts on recognition of human leukocyte antigen-E (HLA-E) by natural killer cells. J Biol Chem. 2013; 288(12):8679-8690. PMC: 3605686. DOI: 10.1074/jbc.M112.409672. View

10.

Stevens J, Joly E, Trowsdale J, Butcher G . Peptide binding characteristics of the non-classical class Ib MHC molecule HLA-E assessed by a recombinant random peptide approach. BMC Immunol. 2001; 2:5. PMC: 33820. DOI: 10.1186/1471-2172-2-5. View

11.

Lee S, Klein J, Haagenson M, Baxter-Lowe L, Confer D, Eapen M . High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007; 110(13):4576-83. DOI: 10.1182/blood-2007-06-097386. View

12.

Green K, Miles J, Tellam J, van Zuylen W, Connolly G, Burrows S . Potent T cell response to a class I-binding 13-mer viral epitope and the influence of HLA micropolymorphism in controlling epitope length. Eur J Immunol. 2004; 34(9):2510-9. DOI: 10.1002/eji.200425193. View

13.

Hirosawa M, HOSHIDA M, Ishikawa M, Toya T . MASCOT: multiple alignment system for protein sequences based on three-way dynamic programming. Comput Appl Biosci. 1993; 9(2):161-7. DOI: 10.1093/bioinformatics/9.2.161. View

14.

Huyton T, Schumacher H, Blasczyk R, Bade-Doeding C . Residue 81 confers a restricted C-terminal peptide binding motif in HLA-B*44:09. Immunogenetics. 2012; 64(9):663-8. DOI: 10.1007/s00251-012-0625-1. View

15.

Probst-Kepper M, Stroobant V, Kridel R, Gaugler B, Landry C, Brasseur F . An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating CD8 T lymphocytes. J Exp Med. 2001; 193(10):1189-98. PMC: 2193327. DOI: 10.1084/jem.193.10.1189. View

16.

Kunze-Schumacher H, Blasczyk R, Bade-Doeding C . Soluble HLA technology as a strategy to evaluate the impact of HLA mismatches. J Immunol Res. 2014; 2014:246171. PMC: 4165401. DOI: 10.1155/2014/246171. View

17.

Sullivan L, Clements C, Rossjohn J, Brooks A . The major histocompatibility complex class Ib molecule HLA-E at the interface between innate and adaptive immunity. Tissue Antigens. 2008; 72(5):415-24. DOI: 10.1111/j.1399-0039.2008.01138.x. View

18.

Lampen M, Hassan C, Sluijter M, Geluk A, Dijkman K, Tjon J . Alternative peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2. Mol Immunol. 2012; 53(1-2):126-31. DOI: 10.1016/j.molimm.2012.07.009. View

19.

Braud V, Allan D, OCallaghan C, Soderstrom K, DAndrea A, Ogg G . HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998; 391(6669):795-9. DOI: 10.1038/35869. View

20.

Drexler H, Matsuo Y . Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma. Leukemia. 2000; 14(5):777-82. DOI: 10.1038/sj.leu.2401778. View